BackApimeds Pharmaceuticals US Overview

Apimeds Pharmaceuticals US Receivables

Track Apimeds Pharmaceuticals US's receivables ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer trimmed avg / median

Loading

Apimeds Pharmaceuticals US Receivables History

Loading

Apimeds Pharmaceuticals US vs. peers: Receivables Comparison

Loading

Apimeds Pharmaceuticals US Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Apimeds Pharmaceuticals US (APUS) FAQ

As of the most recent data (June 2026), APUS shows a receivables of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, APUS's receivables is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Apimeds Pharmaceuticals US is outperforming or lagging.

Tracking APUS's receivables over time shows whether Apimeds Pharmaceuticals US is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Apimeds Pharmaceuticals US's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $0) with ownership activity and broader fundamentals.